West Branch Capital LLC Has $80,000 Stock Position in Pfizer Inc. (NYSE:PFE)

West Branch Capital LLC lessened its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 95.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,795 shares of the biopharmaceutical company’s stock after selling 53,628 shares during the quarter. West Branch Capital LLC’s holdings in Pfizer were worth $80,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Worth Asset Management LLC bought a new position in Pfizer during the first quarter worth $29,000. Briaud Financial Planning Inc acquired a new stake in Pfizer during the 3rd quarter worth about $30,000. GoalVest Advisory LLC raised its position in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer in the 3rd quarter valued at about $34,000. Finally, VisionPoint Advisory Group LLC boosted its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.1 %

PFE stock opened at $27.75 on Friday. The firm has a market capitalization of $157.14 billion, a PE ratio of 77.08, a P/E/G ratio of 1.24 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $42.22. The stock’s 50 day moving average is $27.44 and its 200-day moving average is $29.41.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the business earned $1.14 EPS. The business’s revenue was down 41.3% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Barclays dropped their price target on Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. UBS Group cut their target price on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research note on Thursday, December 14th. Truist Financial decreased their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 14th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $36.88.

Get Our Latest Analysis on PFE

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.